ImmunoCellular Therapeutics to Report Financial Results for the First Quarter 2014 on May 8, 2014

May 1, 2014

LOS ANGELES, May 1, 2014 /PRNewswire/ — ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that it plans to report first quarter 2014 financial results on Thursday, May 8, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO.


    LIVE CALL:               (877) 853-5636 (toll-free);
                             international dial-in: (631)
                             291-4544; conference code

    WEBCAST:                 Interested parties who wish to
                             listen to the webcast should
                             visit the Investor Relations
                             section of ImmunoCellular's
                             website at www.imuc.com, under
                             the Events and Presentations tab.
                             A replay of the webcast will be
                             available one hour after the
                             conclusion of the event.

The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular’s pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.


ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile

Logo- http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO

SOURCE ImmunoCellular Therapeutics, Ltd.

Source: PR Newswire

comments powered by Disqus